Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2008
04/17/2008WO2008043446A1 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl)]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide monohydrate
04/17/2008WO2008043263A1 Isoxazole derivatives and methods of treating diseases
04/17/2008WO2008043246A1 Drug composition for treating 2 type diabetes and its chronicity neopathy
04/17/2008WO2008043211A1 The application of ketanserin for the manufacture of a medicament for preventing cerebral apoplexy
04/17/2008WO2008043183A1 Cyclopropyl-piperazine compounds as calcium channel blockers
04/17/2008WO2008043181A1 Augmenting stem cell populations by modulating t-cell protein tyrosine phosphatase (tc-ptp)
04/17/2008WO2008043180A1 Immunostimulatory composition comprising recombinant bcg mycobacterium expressing mammalian cysteine protease
04/17/2008WO2008043175A1 SOLUBLE β-N-ACETYLGLUCOSAMINIDASE BASED ANTIBIOFILM COMPOSITIONS AND USES THEREOF
04/17/2008WO2008043167A1 Pharmaceutical compositions comprising intra- and extra- granular fractions
04/17/2008WO2008043148A1 The use of a dna damaging agent and a ligand for the treatment of cancer
04/17/2008WO2008027542A3 5-substituted isoindoline compounds
04/17/2008WO2008027395A3 Pharmaceutical compositions of benzodiazepines and methods of use thereof
04/17/2008WO2008027357A3 Pharmaceutical compositions of clonazepam and methods of use thereof
04/17/2008WO2008025111A3 Biodegradable device for intraocular drug delivery
04/17/2008WO2008024390A3 2- (pyrazin-2-yl) -thiazole and 2- (1h-pyraz0l-3-yl) -thiazole derivatives as well as related compounds as stearoyl-coa desaturase (scd) inhibitors for the treatment of metabolic, cardiovascular and other disorders
04/17/2008WO2008024337A3 Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
04/17/2008WO2008024299A3 Combination with bis(thiohydrazide amides) for treating cancer
04/17/2008WO2008022286A3 Small molecule inhibitors of kynurenine-3-monooxygenase
04/17/2008WO2008022164A3 Pyrazine compounds, their use and methods of preparation
04/17/2008WO2008022046A3 Dicer substrate rna peptide conjugates and methods for rna therapeutics
04/17/2008WO2008021936A3 Hepatitis c virus inhibitors
04/17/2008WO2008021933A3 N-aryl or n-heteroaryl pyrazolidine and pyrazolidinone derivatives as prostaglandine receptor inhibitors
04/17/2008WO2008020455A3 Pyrrolo[2,1-c][1,4]benzodiazepine hybrids and a process for the preparation thereof
04/17/2008WO2008020302A3 Heteroaromatic quinoline-based compounds as phosphodiesterase (pde) inhibitors
04/17/2008WO2008020032A8 Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
04/17/2008WO2008019871A3 Novel salts of the active substance rasagiline
04/17/2008WO2008019820A3 Crystal form of epothilone b and use in pharmaceutical compositions
04/17/2008WO2008019395A9 Compounds for improving learning and memory
04/17/2008WO2008019372A3 2-aminobenzoxazole carboxamides as 5ht3 modulators
04/17/2008WO2008019306A3 Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
04/17/2008WO2008019109A3 Stabilization of lorazepam
04/17/2008WO2008017932A3 Heterocycles useful as inhibitors of carbonic anhydrase
04/17/2008WO2008017398A3 Polymorphic forms of rosiglitazone base
04/17/2008WO2008016665A3 Imidazoacridine compounds for treating flt3 -mediated disorders
04/17/2008WO2008015535A3 Composition with improved antioxidant and antiglycating activity
04/17/2008WO2008013660A3 Inhibitors of advanced glycation end products
04/17/2008WO2008012031A3 Blockers of gsk3 for the prevention and treatment of pemphigus vulgaris
04/17/2008WO2008011539A3 Anesthetic compounds
04/17/2008WO2008011117A3 Antiviral protease inhibitors
04/17/2008WO2008011005A3 Antiangiogenic agents
04/17/2008WO2008010238A3 Antidiabetic azabicyclo [3. 1. 0] hexan compounds
04/17/2008WO2008010061A3 3-azabicyclo [3.1.0] hexane vanilloid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
04/17/2008WO2008009589A3 Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient
04/17/2008WO2008008887A3 Gpr119 agonists for treating metabolic disorders
04/17/2008WO2008006625A3 Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
04/17/2008WO2008006064A3 Biomimetic polymers and uses thereof
04/17/2008WO2008005580A3 Formulation for treatment of acne
04/17/2008WO2008005528A3 Compositions and methods for the modulation of detrusor activity
04/17/2008WO2008004206A3 Carotenoid compositions useful for whitening skin
04/17/2008WO2008003858A3 Use of derivatives of imidazo[1, 2-a]pyridine-2-carboxamides in therapeutics
04/17/2008WO2008002571B1 Human protein tyrosine phosphatase inhibitors and methods of use
04/17/2008WO2008002570B1 Human protein tyrosine phosphatase inhibitors and methods of use
04/17/2008WO2008002568A3 Active agent formulations, methods of making, and methods of use
04/17/2008WO2008001236A3 Alkalized local anesthetic in bag
04/17/2008WO2008000745A3 Adenosine derivatives for the treatment of pain
04/17/2008WO2007147771A3 Tetralin and indane derivatives and uses thereof
04/17/2008WO2007147505A3 A system for controlling administration of anaesthesia
04/17/2008WO2007147371A3 Pharmaceutical composition for oral administration
04/17/2008WO2007146323A3 Substituted cyanopyridines as protein kinase inhibitors
04/17/2008WO2007146085A3 Creatine phosphate prodrugs, compositions and uses thereof
04/17/2008WO2007144785A3 Ryanodine receptor inhibitors and methods relating thereto
04/17/2008WO2007144084A3 Type-2 diabetes combination wafer
04/17/2008WO2007144083A3 Ache-nmda combination wafer
04/17/2008WO2007141224A3 Jnk inhibitors for treatment of skin diseases
04/17/2008WO2007139992A3 ALDOSTERONE SYNTHASE AND/OR 11β-HYDROXYLASE INHIBITORS
04/17/2008WO2007138381A3 Phosphonated oxazolidinones and uses thereof for the prevention and treatment of bone and joint infections
04/17/2008WO2007137071A3 Compositions of r(+) and s(-) pramipexole and methods of using the same
04/17/2008WO2007135569A3 Methods of treating canine osteosarcoma
04/17/2008WO2007134845A3 Olanzapine pharmaceutical composition
04/17/2008WO2007133749A3 Methods and compositions for treating and preventing peripheral nerve damage
04/17/2008WO2007129162A3 Pharmaceutical preparations for transdermal use
04/17/2008WO2007127951A3 Compositions and methods involving mda-7 for the treatment of cancer
04/17/2008WO2007125423A3 Molecules which bind to the dimerization initiation site (dis) of hiv rna, their synthesis and their applications as drugs
04/17/2008WO2007124869A3 Liquid pharmaceutical formulation
04/17/2008WO2007123949A3 Cannabinoid receptor modulators
04/17/2008WO2007118832A3 Amino derivatives of androstanes and androstenes as medicaments for cardiovascular disorders
04/17/2008WO2007117639A9 Synthesis of tetracyclines and analogues thereof
04/17/2008WO2007115836A3 Tetrahydronaphtol-derivatives and use thereof
04/17/2008WO2007115286A3 Combinations of therapeutic agents for treating cancer
04/17/2008WO2007114978A3 Method for treating hiv infection through co-administration of tipranavir and pa-457
04/17/2008WO2007107835A3 Stable liquid formulations of antiepileptic agents
04/17/2008WO2007099410A3 Formulations of fispemifene
04/17/2008WO2007099377A3 Cancer treatments
04/17/2008WO2007095178A3 Methoxypolyethylene glycol thioester chelate and uses thereof
04/17/2008WO2007085895A3 Fap inhibitors
04/17/2008WO2007076367A3 Rnai-mediated inhibition of rho kinase for treatment of ocular hypertension / glaucoma
04/17/2008WO2007070626A3 Certain chemical entities, compositions and methods
04/17/2008WO2007070426A9 Sexual dysfunction
04/17/2008WO2007070376A3 Diagnosis, prognosis and monitoring of disease progression of systemic lupus erythematosus through blood leukocyte microarray analysis
04/17/2008WO2007056517A3 Pharmaceutical salts and polymorphs of n- (5-chl0r0-2-pyridinyl) -2- [ [4- [ (dimethylamino) iminomethyl] benzoyl] amino] -5-meth oxy-benzamide, a factor xa inhibitor
04/17/2008WO2007056340A3 Disinfectant and antiseptic pyridinium and thiazolium compounds and methods of using the same
04/17/2008WO2007052164A8 A pharmaceutical formulation containing olanzapine
04/17/2008WO2007042571A8 Novel pyrimidine-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels
04/17/2008WO2007028341A8 Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids
04/17/2008WO2006128172A3 Method for treating b cell regulated autoimmune disorders
04/17/2008WO2006127987A3 Treatment of eye disorders with sirtuin modulators
04/17/2008WO2006083710A3 Use of 5-ht4 agonist for treating delayed gastric emptying which may be induced by a proton pump inhibitor
04/17/2008WO2005020903A3 Methods of improving the safety of zonisamide therapy
04/17/2008US20080091263 Apparatus and Methods for Preventing or Treating Failure of Hemodialysis Vascular Access and Other Vascular Grafts
04/17/2008US20080091024 Processes for the production of substituted 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazoles